Background: LncRNAs are considered as novel biological regulators and potential cancer biomarkers. LncRNAs MVIH and AK058003 are associated with microvascular invasion in HCC. In BC, upregulated MVIH and AK058003 expression levels have been shown to promote cell proliferation, though LncRNA-AK058003 acts as a tumor suppressor in HCC. Methods: Blood samples were collected from 30 healthy women and 30 female BC patients. RNA was extracted from the blood of both groups, and cDNA was then synthesized. Real-time PCR was used to measure the expression level of LncRNA-AK058003 and MVIH. Results: The expression level of two LncRNAs in the blood samples of BC patients increased significantly compared with healthy individuals. The levels of AK058003 and MVIH were not associated with lymph node metastasis ( p = 0.402 and p = 0.39), tumor size ( p = 0.76 and p = 0.461), and TNM stage ( p = 0.574 and p = 0.711), respectively. Conclusion : As per our findings, LncRNA-AK058003 could serve as a suitable indicator for low stage of BC. In addition, the increased level of LncRNA-MVIH could be considered as a biomarker for BC, which needs more evaluation in the future.

The delay in diagnosis and treatment of breast cancer results in low survival rates and high mortality. Thus, it is essential to characterize new therapeutic targets and prognostic breast cancer biomarkers. The rising evidence suggested that long non-coding RNAs (lncRNAs) expression levels are deregulated in human cancers and can use as biomarkers for the rapid diagnosis of breast cancer. In the present study, a Quantitative Real-time polymerase chain reaction (qRT-PCR) technique was used to measure twenty oncogenic and tumor suppressor lncRNAs expression levels in whole blood samples of breast cancer patients and normal controls. Blood samples from 30 healthy women and 30 female breast cancer patients were collected. Then cDNA was synthesized from the extracted RNA blood. The expression level of lncRNAs measured and analyzed by LinReg PCR and REST software and the correla tion between lncRNAs dysregulation and clinical characteristics and prognosis were also analyzed by SPSS software. The comparison between the expression levels of lncRNAs in the blood samples of breast cancer patients compared with healthy individuals revealed that some lncRNAs (MEG3, NBAT1, NKILA, GAS5, EPB41L4A-AS2, ZFAS1, MVIH, Z38, and BC040587) were down regulated. In contrast, other lncRNAs (H19, SPRY4-IT1, UCA1, AC026904.1, CCAT1) were up-regulated, signi cantly. It was shown that the expression levels of NKILA, NBAT1, and ZFAS1 lncRNAs were related to tumor size, and BC040587expression level related to age, node metastasis, tumor size, and grade (P<0.05). The association between H19 and SPRY4-IT1 lncRNAs with HER-2 was con rmed statistically (P<0.05). Our data highlighted the correlation of BC040587, H19, and SPRY4-IT1 lncRNAs with clinicopathological traits in breast cancer patients suggesting their future applications as novel biomarkers and therapeutic targets in breast cancer. In conclusion, circulating lncRNAs could consider as the prognostic and predictive markers in breast cancer.

The delay in diagnosis and treatment of breast cancer results in low survival rates and high mortality. Thus, it is essential to characterize new therapeutic targets and prognostic breast cancer biomarkers. The rising evidence suggested that long non-coding RNAs (lncRNAs) expression levels are deregulated in human cancers and can use as biomarkers for the rapid diagnosis of breast cancer. In the present study, a Quantitative Real-time polymerase chain reaction (qRT-PCR) technique was used to measure twenty oncogenic and tumor suppressor lncRNAs expression levels in whole blood samples of breast cancer patients and normal controls. Blood samples from 30 healthy women and 30 female breast cancer patients were collected. Then cDNA was synthesized from the extracted RNA blood. The expression level of lncRNAs measured and analyzed by LinReg PCR and REST software and the correla­tion between lncRNAs dysregulation and clinical characteristics and prognosis were also analyzed by SPSS software. The comparison between the expression levels of lncRNAs in the blood samples of breast cancer patients compared with healthy individuals revealed that some lncRNAs (MEG3, NBAT1, NKILA, GAS5, EPB41L4A-AS2, ZFAS1, MVIH, Z38, and BC040587) were down regulated. In contrast, other lncRNAs (H19, SPRY4-IT1, UCA1, AC026904.1, CCAT1) were up-regulated, significantly. It was shown that the expression levels of NKILA, NBAT1, and ZFAS1 lncRNAs were related to tumor size, and BC040587expression level related to age, node metastasis, tumor size, and grade (P<0.05). The association between H19 and SPRY4-IT1 lncRNAs with HER-2 was confirmed statistically (P<0.05). Our data highlighted the correlation of BC040587, H19, and SPRY4-IT1 lncRNAs with clinicopathological traits in breast cancer patients suggesting their future applications as novel biomarkers and therapeutic targets in breast cancer. In conclusion, circulating lncRNAs could consider as the prognostic and predictive markers in breast cancer.